Last reviewed · How we verify
Cosentyx — Competitive Intelligence Brief
marketed
Interleukin-17A
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cosentyx (Cosentyx) — Janssen Research & Development, LLC.
Comparator set (5 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cosentyx TARGET | Cosentyx | Janssen Research & Development, LLC | marketed | Interleukin-17A | ||
| Bimzelx | BIMEKIZUMAB | Ucb Japan Co., Ltd. | marketed | Interleukin-17A | 2021-01-01 | |
| Cosentyx | secukinumab | Novartis | marketed | IL-17A antagonist | Interleukin-17A (IL-17A) | 2015-01-01 |
| Subcutaneous injection of Secukinumab | Subcutaneous injection of Secukinumab | Peking Union Medical College | marketed | IL-17A inhibitor (monoclonal antibody) | IL-17A (Interleukin-17A) | |
| Taltz | Taltz | Yale University | marketed | Interleukin-17A | ||
| BIMZELX | BIMEKIZUMAB-BKZX | UCB INC | marketed | Interleukin-17A, Interleukin-17F, Interleukin-17AF |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Cosentyx — Competitive Intelligence Brief. https://druglandscape.com/ci/cosentyx. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab